CTLA4 and neoplasm: Blocking CTLA-4 reduces the infiltration of MDSCs in the tumor microenvironment (TME), diminishing their immunosuppressive effects and potentially enhancing the efficacy of PD-1/PD-L1 inhibitors in tumor suppression (Rotte, 2019).